Dasiglucagon for treating severe hypoglycaemia due to type 1 diabetes in children aged under 6 years

Dasiglucagon is in clinical development for treating severe hypoglycaemia (very low blood sugar) in children with type 1 diabetes (T1D). Hypoglycaemia occurs when blood sugar levels drop too low, leading to symptoms such as shakiness, pounding heart, sweatiness, headache, drowsiness, and difficulty concentrating. In young children, behavioural changes such as irritability, agitation, quietness, and tantrums, may be prominent. Severe hypoglycaemia is defined as having low blood glucose levels that requires assistance from another person to treat. Timely management of hypoglycaemia is critical for individuals with T1D, as untreated episodes can be life-threatening. Current treatments require preparation before administration, which can delay response times in emergency situations. In contrast, dasiglucagon is a ready-to-use, subcutaneous (SC) injection designed to rapidly raise blood glucose levels.